Well Referenced

Tag: RigiScan

Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response

This randomized controlled trial investigated the effects of combining low-dose intranasal PT-141 (bremelanotide) with sildenafil in 19 men with erectile dysfunction (ED). The study found that the combination significantly enhanced erectile response during visual sexual stimulation compared to sildenafil alone, without increasing adverse events. PT-141, a melanocortin receptor agonist, acts

Read More »
June 26, 2025 No Comments

Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra

This randomized controlled trial evaluated the safety, pharmacokinetics, and pharmacodynamic effects of PT-141, a melanocortin receptor agonist, in both healthy male subjects and patients with erectile dysfunction (ED) who had an inadequate response to sildenafil (Viagra). The study found that doses greater than 1.0 mg in healthy males and doses

Read More »
June 26, 2025 No Comments

Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II

This randomized controlled trial evaluated the effects of Melanotan II, a melanocortin receptor agonist, on penile erection and sexual desire in men with psychogenic and organic erectile dysfunction (ED). Among 20 participants, 85% experienced spontaneous penile erections without sexual stimulation, and 68% reported increased sexual desire after Melanotan II administration,

Read More »
June 26, 2025 No Comments